LONG-TERM EXPERIENCE WITH TOPIRAMATE AS ADJUNCTIVE THERAPY AND AS MONOTHERAPY IN PATIENTS WITH PARTIAL ONSET SEIZURES - RETROSPECTIVE SURVEY OF OPEN-LABEL TREATMENT

Because initial studies of new antiepileptic drugs (AEDs) are add-on t rials in refractory patient populations, their effectiveness as monoth erapy is usually not apparent until relatively later in their developm ent programs. The novel AED topiramate (TPM) has been found efficaciou s as adjunctive therapy in controlled, randomized trials in adults wit h partial onset seizures. We report a retrospective analysis of TPM as AED monotherapy in 214 patients from five centers who received TPM in investigational trials. Of this total, 136 (64%) were still receiving TPM at the time of the analysis, with a mean treatment duration of 2. 5 years. One-third of the patients have been successfully converted to TPM monotherapy, and 62% of those converted have been seizure-free fo r at least 3 months. The results of this analysis suggest that TPM may prove to be a valuable new AED for both monotherapy and add-on therap y in partial onset epilepsy.